IN
INDP.US Indaptus Therapeutics Inc
- Market cap
- USD 422M
- P/E
- -
- P/B
- 37.37x
- ROE
- -69.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INDP.US undervalued?
Graham numberThe Graham number of Indaptus Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Indaptus Therapeutics Inc fundamental analysis
No fundamental analysis for Indaptus Therapeutics Inc yet.
Indaptus Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced …
Full company profileIndaptus Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Indaptus Therapeutics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -701K | -829K | -859K | -854K | -852.00 | -1.40K | -1.78K | -1.28K | -735.00 | - | - |
| Operating Income | -13.8M | -29.4M | -43.3M | -34.9M | -3.60M | -7.73M | -14.9M | -16.4M | -15.4M | -19.8M | -6.81M |
| EBITDA | -13.1M | -28.6M | -42.6M | -46.1M | -3.60M | -7.71M | -14.3M | -15.4M | -15.0M | -20.8M | -7.22M |
| Net Income | -13.4M | -28.9M | -43.5M | -47.6M | -3.58M | -7.71M | -14.3M | -15.4M | -15.0M | -20.8M | -7.18M |
| EPS | -2,615 | -3,667 | -3,127 | -3,157 | -206 | -53 | -49 | -51 | -45 | -22 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 24.7M | 64.5M | 61.5M | 21.3M | 1.78M | 40.6M | 28.1M | 14.9M | 7.34M | 9.31M | 31.2M |
| Total Liabilities | 2.02M | 5.75M | 7.97M | 9.75M | 2.02M | 4.68M | 3.43M | 2.85M | 3.39M | 6.16M | 20.9M |
| Shareholders' Equity | 22.7M | 58.8M | 53.5M | 11.5M | -238K | 35.9M | 24.6M | 12.1M | 3.94M | 3.15M | 10.3M |
| Cash & Short-term Investments | 18.3M | 55.2M | 40.6M | 10.1M | 1.64M | 39.1M | 26.4M | 13.4M | 5.79M | 8.51M | 30.6M |
| Total Debt | - | - | - | 1.34M | 169K | 169K | 80.5K | 175K | 84.2K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.0M | -22.1M | -39.1M | -29.0M | -3.32M | -11.3M | -13.1M | -13.4M | -12.3M | -14.8M | -13.8M |
| Capital Expenditure | 482K | 5.00M | 9.60M | 921K | 8.21M | 3.85K | 173K | 5.00 | 0.00 | 4.00 | 8.00 |
| Free Cash Flow | -12.5M | -27.1M | -48.7M | -30.0M | -3.32M | -11.3M | -13.3M | -13.4M | -12.3M | -14.8M | -13.8M |
| Ratios | |||||||||||
| ROE | -58.9% | -49.2% | -81.3% | -412.6% | - | -21.5% | -58.2% | -127.7% | -380.8% | -661.5% | -69.5% |
| ROA | -54.1% | -44.8% | -70.8% | -223.7% | -201.6% | -19.0% | -51.0% | -103.3% | -204.7% | -223.9% | -23.0% |
| Debt to Equity | - | - | - | 0.12x | - | 0.00x | 0.00x | 0.01x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Indaptus Therapeutics Inc dividends
Indaptus Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:28 on Jun 27, 2025.
Who owns Indaptus Therapeutics Inc
- Insiders 70.71%
- Institutions 0.46%
- Public & others 28.84%
- Shares outstanding 133M
- Free float 39.3M
Top funds holding INDP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 69.4K | 0.05% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 57.5K | 0.04% | +400.78% | Sep 2026 |
| Fidelity Series Total Market Index | 20.4K | 0.02% | +418.94% | Sep 2026 |
| Fidelity Total Market Index | 19.6K | 0.01% | +4,151.30% | Sep 2026 |
| Morgan Stanley Pathway Sm-Md Cp Eq ETF | 11.1K | 0.01% | 0.00% | Oct 2026 |
Top institutions holding INDP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 206K | 0.15% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 56.5K | 0.04% | +109.09% | Jun 2026 |
| Jane Street Group LLC | 53.8K | 0.04% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 33.7K | 0.03% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 14.0K | 0.01% | 0.00% | Jun 2026 |
| Millennium Management LLC | 11.6K | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 8.94K | 0.01% | +231.33% | Jun 2026 |
| UBS Group AG | 478.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 17.00 | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Indaptus Therapeutics Inc company profile
- Company name
- Indaptus Therapeutics Inc
- Ticker
- INDP.US
- Exchange
- USA Stocks
- Listed since
- Aug 4, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- Three Columbus Circle, New York, NY, United States, 10019
- Phone
- 646 427 2727
- Website
- indaptusrx.com
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics Inc management
2- Mr. Junyi DaiCEO & Chairman · born 1987
- Mr. Yu DingChief Financial Officer · born 1975